The medical cannabis market in Europe is experiencing a period of dynamic development, presenting a picture of changes in both the medical and legal spheres. Recent market analyzes paint a picture of a significant increase in the value of this market, from $3.4 billion in 2022 to a projected $9.7 billion in 2028.
This growth, characterized by an impressive annual growth rate of 19%, is the result of a number of factors that are changing the medical landscape marijuana in Europe. In this article, we will look at key aspects of this phenomenon by analyzing the Europe Medical Cannabis Market Forecast to 2028 report published by Research and Markets, taking into account both the legal and social as well as economic factors that are driving this development.
Read more about the European cannabis market and find the latest cannabis news from around the world with the Hemp.im mobile app.
Key growth factors for the European cannabis market
The development of the medical cannabis market in Europe is driven by a number of important factors that together contribute to its dynamic growth.
Legalization and growing acceptance : In recent years, there has been a significant shift in attitudes towards medical cannabis in many European countries. Germany, being one of the leaders in this field, legalized medical cannabis already in 2017, which paved the way for market development and an increase in the number of patients using cannabis-based therapy.
France, meanwhile, began a two-year pilot program in 2021 to assess the effectiveness and feasibility of using medical cannabis to treat specific conditions. In the UK, following the legalization of medical cannabis in 2018, we have seen regulations continually adapt to facilitate access to therapy for patients. Poland legalized medical cannabis on November 1, 2017, and only in the first half of 2023, 1,589 kg of hemp from Portuguese crops reached Poland , becoming the second largest importer, right after Germany.
Diverse market and increasing availability : The medical cannabis market in Europe is characterized by a diversity of product forms available, from dry forms to extracts, with increasing acceptance of the latter form. This diversity allows patients to choose the product best suited to their needs and preferences.
Research and Investment Growth : Market growth is also supported by increasing investments in research on medical marijuana and its potential therapeutic applications. Such investments not only increase the availability and quality of products, but also expand knowledge about their effectiveness and safety
Cannabis market segmentation analysis:
The segmentation of the medical marijuana market in Europe reflects its complexity and dynamics. Key aspects of this segmentation include:
Dried Forms and Extracts : The market is segmented into dried forms of marijuana and extracts. Extracts are more popular due to their convenience of use and effectiveness. They are also more commonly used in medical therapies due to easier dosing and stability.
Pain management : The pain management sector dominates the market, reflecting the growing interest in using cannabis to treat chronic pain as well as conditions such as multiple sclerosis and cancer.
Other Uses : Medical cannabis is also used to treat Tourette’s, Alzheimer’s disease, depression, sleep disorders, anxiety, and other conditions, demonstrating its versatility and therapeutic potential.
Retail pharmacies : This is the primary distribution channel that offers patients direct access to medical cannabis products.
E-commerce platforms : The increase in the popularity of online shopping is also visible in the medical cannabis sector, which facilitates access and selection of products for patients. This method has not yet been introduced in Poland, so patients must make purchases in person at pharmacies.
Market overview in individual countries
The medical cannabis market in Europe varies across countries, with Germany leading in terms of market share and growth rate. An overview of the situation in selected European countries is as follows:
Germany : As the leader of the medical cannabis market in Europe, Germany stands out for its extensive market and well-developed regulatory system. The legalization of cannabis for medical purposes in 2017 led to a significant increase in the number of patients and product availability. Medical cannabis is also cultivated in Germany, which affects the availability and lower prices of products.
United Kingdom : Since the legalization of medical cannabis in 2018, the UK market has grown steadily, despite some challenges with availability and regulation. The UK government continues to work to improve access to cannabis-based therapies.
France : France, although still in its early stages, has launched a pilot program to assess the effectiveness and safety of medical cannabis. This step may contribute to further market development.
Italy, Spain and the Rest of Europe : Other countries such as Italy and Spain are also seeing an increase in interest in medical cannabis. Italy, with a well-developed medical cannabis program, continues to advance in regulation and availability. In the report “Europe Medical Cannabis Market Forecast to 2028”, Poland was included in the “rest of Europe” category, although everything indicates that we are one of the leaders in the use of cannabis for medical purposes.
The future of the medical cannabis market in Europe
Forecasts for the future of the medical cannabis market in Europe are promising. The dynamic growth and development is expected to continue:
Developments in Research and Innovation : Increasing investment in research is expected to advance understanding of the potential uses of medical cannabis and open up new therapeutic opportunities. This, in turn, could lead to an expansion of the list of conditions eligible for treatment with cannabis.
Regulation and Accessibility : It is expected that European countries will continue to work on improving laws to facilitate access to medical cannabis, making it more accessible to patients.
Increase in Awareness and Acceptance : As more and more data proves the effectiveness of medical cannabis in treating various medical conditions, public awareness and acceptance is expected to increase, which will also fuel the market growth.
The medical cannabis market in Europe is on the verge of significant growth and development. The market value, which is expected to grow from $3.41 billion in 2022 to $9.70 billion in 2028, reflects the growing acceptance, legalization and interest in the medical uses of cannabis.
Countries such as Germany, Poland, the UK and France are playing a key role in this process, helping to shape the future of this sector in Europe. Increased awareness, research development and regulatory improvements will continue to expand and mature the market, which may open up new therapeutic options for patients across the continent.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The End of Cannabis in Thailand? The Ministry of Health Introduces a Ban
This legislative change represents a decisive turn in the drug policy of a country that until recently was a leader...
Solana and Meme Coins Are Hugely Positive – Bitcoin Is Driving the Market
As the number one Solana meme coin, BONK is currently up a good 80 percent weekly. You can turn the...
Grifols Rebounds 20% on the Stock Market Due to Its Cash Flow Data and the Sale of Shanghai Raas
Grifols' guidance for 2024 estimates recording an adjusted EBITDA of more than 1.8 billion euros, as well as a free...
When to Buy, When to Sell?Look at the Dow Jones Dividend Yield
The next time the Dow Jones Dividend Yield increased to above 3% was during the March 2020 Flash Crash, where...
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [1xBet Affiliate Program]
Wanna discover one weird sports betting niche with plenty of low-hanging fruit just waiting for you to exploit? Then read...
Fintech2 weeks ago
Bold Will Have a Debit Card and Will Start Pilot Testing of the Account in March
Biotech6 days ago
Rovi Will Double Production to Sell to Third Parties After the Drop in Sales Post Covid-19
Fintech2 weeks ago
Solaris Bank Ends Months of Trepidation with ADAC Deal
Impact Investing5 days ago
Stellantis Partners with Ayvens to Supply 500,000 Electric Cars